Medicines in Development for Mental Illnesses 2016 Report

PhRMA April 22, 2016

Biopharmaceutical research companies are developing more than 130 medicines for mental illnesses. Mental illnesses exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that one in five American adults and children experience a mental illness in any given year amounting to more than $317 billion annually in the U.S. in lost wages, health care expenditures and disability benefits.

Over the past half century, biopharmaceutical research has helped transform this misunderstood set of diseases into often highly treatable conditions. However, additional therapeutic options are needed for patients not helped by existing treatments and to address unmet medical needs. Biopharmaceutical companies are working closely with patients, regulators, academia and clinicians on the cutting-edge medicine and research needed to bring new medicines to patients.